Taro Pharm Inds (TARO) 161.14 $TARO
Taro Pharma ups EPS 29% in FQ3
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 9:24AM CST
TARO: 161.14 (-1.44)
Taro posts better operating income of USD159.3m for quarter ended 31 December 2014
M2 - Wed Feb 11, 5:18AM CST
Pharmaceutical company Taro Pharmaceutical Industries (NYSE:TARO) disclosed on Tuesday that it recorded operating income of USD159.3m, or 67.0% of net sales, for the three months ended 31 December 2014.
TARO: 161.14 (-1.44)
Taro Pharmaceutical reports FQ3 earnings
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:51PM CST
TARO: 161.14 (-1.44)
Taro Provides Results for December 31, 2014
Business Wire - Tue Feb 10, 3:25PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"
today provided unaudited financial results for the three months and nine months ended December 31, 2014.
TARO: 161.14 (-1.44)
Pfizer Pays A Pretty Penny For Hospira: Here's What You Need To Know
Brendan O'Boyle - at Seeking Alpha - Tue Feb 10, 8:49AM CST
ABT: 46.09 (+0.87), TARO: 161.14 (-1.44), PFE: 34.64 (-0.23), MYL: 55.85 (+1.34), EPRS: 7.67 (+0.67), TEVA: 56.77 (-0.58), HSP: 87.35 (unch)
Taro to Announce Third Quarter Results on February 10, 2015
Business Wire - Thu Feb 05, 3:07PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2014, after the close of market on Tuesday, February 10, 2015.
TARO: 161.14 (-1.44)
Spirit Air, Other Leading Stocks Shaping New Bases
at Investor's Business Daily - Thu Jan 29, 5:04PM CST
A number of top stocks in Your Weekly Review are working on bases, as strong jobs data boosted the major averages Thursday. Still, the market's uptrend remains under pressure, which adds risk to new purchases. Investors should consider buying only...
SAVE: 79.32 (-0.80), CSTE: 62.62 (+0.15), TARO: 161.14 (-1.44), APOG: 45.54 (+0.27), FRGI: 61.80 (-0.33)
Dermatitis Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014-2015
M2 - Fri Jan 16, 5:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/449cq9/dermatitis_market) has announced the addition of the "Dermatitis Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Dermatitis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Allergan, Inc. - Astellas Pharma US, Inc. - Horizon Pharma, Inc. - Quinnova Pharmaceuticals, Inc. - Merck & Co., Inc. - Bayer HealthCare Pharmaceuticals Inc. - Stiefel Laboratories, Inc. - AbbVie Inc. - Pfizer Inc. - Pharmacia & Upjohn, Inc. - Roxane Laboratories, Inc. - PharmaDerm - Prestium Pharma, Inc. - Aqua Pharmaceuticals, LLC - Lilly USA, LLC - Novartis Pharmaceuticals Corporation - Astellas Pharma Inc. - Organon USA Inc. - Apothecon Inc - Schering-Plough HealthCare Products, Inc - Schering-Plough Corporation (Inactive) - Taro Pharmaceutical Industries Ltd. - Merck Sharp & Dohme Corp. - Onset Dermatologics - Standard Homeopathic Company - Sandoz Inc. - Panray Corporation - UCB, Inc. - Concordia Pharmaceuticals Inc. - Medimetriks Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/44...tis_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AGN: 229.49 (+1.87), TARO: 161.14 (-1.44), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), HZNP: 16.84 (-0.41), ABBV: 58.05 (+1.00), NVS: 102.20 (-0.17)
3 Reasons To Be Bullish On Generic Drug Firm Akorn
at Investor's Business Daily - Thu Jan 15, 1:12PM CST
With a top IBD Composite Rating of 99 and four straight quarters of accelerated EPS growth, generic drug maker Akorn (AKRX) is already doing pretty well. A new analyst report outlines even more reasons to be bullish on the stock for 2015. Lake...
ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), TARO: 161.14 (-1.44), AKRX: 47.28 (-0.25), MYL: 55.85 (+1.34), NVS: 102.20 (-0.17)
Taro Announces Results of Its Annual General Meeting of Shareholders
Business Wire - Wed Dec 24, 12:30PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company" announced that the Company held its annual general meeting of shareholders on December 22, 2014, at the offices of Meitar Liquornik Geva Leshem Tal, located at 16 Abba Hillel Road, Gallery Floor, Ramat Gan (the "Annual General Meeting" .
TARO: 161.14 (-1.44)
Stock Movers: Why 4 Big Drug Stocks Are Rising Today
at Investor's Business Daily - Tue Nov 18, 1:38PM CST
Drugmakers clustered near the top of IBD's Stocks On The Move list Tuesday afternoon. Actavis (ACT), an Ireland-based maker of generic and branded drugs, shot up more than 7% in huge volume in Tuesday afternoon trading on the stock market today. That...
AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), TARO: 161.14 (-1.44), GILD: 101.90 (+1.10)
Taro Pharmaceutical Industries' (TARO) CEO Kal Sundaram on Q2 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:07PM CST
TARO: 161.14 (-1.44)
Taro Pharma ups earnings 49% in FQ2
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 12:48PM CST
TARO: 161.14 (-1.44)
Taro Pharmaceutical EPS of $3.35
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:43AM CST
TARO: 161.14 (-1.44)
Taro Provides Results for September 30, 2014
Business Wire - Sun Nov 09, 10:36AM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company" today provided unaudited financial results for the three months and six months ended September 30, 2014.
TARO: 161.14 (-1.44)
Taro reports November 9
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:42PM CST
TARO: 161.14 (-1.44)
Taro to Announce Second Quarter Results on November 9, 2014
Business Wire - Wed Nov 05, 2:26PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2014, on Sunday, November 9, 2014.
TARO: 161.14 (-1.44)
Use The Relative Strength Line To Qualify A Breakout
at Investor's Business Daily - Wed Oct 29, 5:40PM CDT
Stock charts are a collection of facts and tools: price, volume, moving averages. All of them help you understand how a stock and its investors are responding to market input and supply and demand. One very helpful but often lesser-used tool is the...
TARO: 161.14 (-1.44)
Glaucoma Market Analysis 2014-2015 - API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Oct 02, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qn2l4v/glaucoma_market) has announced the addition of the "Glaucoma- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Glaucoma- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Allergan, Inc. - Merck & Co., Inc. - Alcon, Inc. - Taro Pharmaceutical Industries Ltd. - Pharmacia & Upjohn, Inc. - Teva Pharmaceuticals USA, Inc. - Akorn, Inc. - Pfizer Inc. - Alcon Laboratories, Inc. - Bausch & Lomb Incorporated - JHP Pharmaceuticals, LLC - Mobius Therapeutics, LLC - American Regent, Inc. For more information visit http://www.researchandmarkets.com/research/qn...oma_market
AGN: 229.49 (+1.87), TARO: 161.14 (-1.44), AKRX: 47.28 (-0.25), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07)
Taro Provides Results for Quarter Ended June 2014
Business Wire - Thu Aug 07, 5:47PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company" today provided unaudited financial results for the three month period ended June 30, 2014.
TARO: 161.14 (-1.44)
Taro Pharma ups EPS 29% in FQ3
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 9:24AM CST
TARO: 161.14 (-1.44)
Taro posts better operating income of USD159.3m for quarter ended 31 December 2014
M2 - Wed Feb 11, 5:18AM CST
Pharmaceutical company Taro Pharmaceutical Industries (NYSE:TARO) disclosed on Tuesday that it recorded operating income of USD159.3m, or 67.0% of net sales, for the three months ended 31 December 2014.
TARO: 161.14 (-1.44)
Taro Pharmaceutical reports FQ3 earnings
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:51PM CST
TARO: 161.14 (-1.44)
Taro Provides Results for December 31, 2014
Business Wire - Tue Feb 10, 3:25PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"
today provided unaudited financial results for the three months and nine months ended December 31, 2014. TARO: 161.14 (-1.44)
Pfizer Pays A Pretty Penny For Hospira: Here's What You Need To Know
Brendan O'Boyle - at Seeking Alpha - Tue Feb 10, 8:49AM CST
ABT: 46.09 (+0.87), TARO: 161.14 (-1.44), PFE: 34.64 (-0.23), MYL: 55.85 (+1.34), EPRS: 7.67 (+0.67), TEVA: 56.77 (-0.58), HSP: 87.35 (unch)
Taro to Announce Third Quarter Results on February 10, 2015
Business Wire - Thu Feb 05, 3:07PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2014, after the close of market on Tuesday, February 10, 2015.
TARO: 161.14 (-1.44)
Spirit Air, Other Leading Stocks Shaping New Bases
at Investor's Business Daily - Thu Jan 29, 5:04PM CST
A number of top stocks in Your Weekly Review are working on bases, as strong jobs data boosted the major averages Thursday. Still, the market's uptrend remains under pressure, which adds risk to new purchases. Investors should consider buying only...
SAVE: 79.32 (-0.80), CSTE: 62.62 (+0.15), TARO: 161.14 (-1.44), APOG: 45.54 (+0.27), FRGI: 61.80 (-0.33)
Dermatitis Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014-2015
M2 - Fri Jan 16, 5:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/449cq9/dermatitis_market) has announced the addition of the "Dermatitis Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Dermatitis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Allergan, Inc. - Astellas Pharma US, Inc. - Horizon Pharma, Inc. - Quinnova Pharmaceuticals, Inc. - Merck & Co., Inc. - Bayer HealthCare Pharmaceuticals Inc. - Stiefel Laboratories, Inc. - AbbVie Inc. - Pfizer Inc. - Pharmacia & Upjohn, Inc. - Roxane Laboratories, Inc. - PharmaDerm - Prestium Pharma, Inc. - Aqua Pharmaceuticals, LLC - Lilly USA, LLC - Novartis Pharmaceuticals Corporation - Astellas Pharma Inc. - Organon USA Inc. - Apothecon Inc - Schering-Plough HealthCare Products, Inc - Schering-Plough Corporation (Inactive) - Taro Pharmaceutical Industries Ltd. - Merck Sharp & Dohme Corp. - Onset Dermatologics - Standard Homeopathic Company - Sandoz Inc. - Panray Corporation - UCB, Inc. - Concordia Pharmaceuticals Inc. - Medimetriks Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/44...tis_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AGN: 229.49 (+1.87), TARO: 161.14 (-1.44), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), HZNP: 16.84 (-0.41), ABBV: 58.05 (+1.00), NVS: 102.20 (-0.17)
3 Reasons To Be Bullish On Generic Drug Firm Akorn
at Investor's Business Daily - Thu Jan 15, 1:12PM CST
With a top IBD Composite Rating of 99 and four straight quarters of accelerated EPS growth, generic drug maker Akorn (AKRX) is already doing pretty well. A new analyst report outlines even more reasons to be bullish on the stock for 2015. Lake...
ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), TARO: 161.14 (-1.44), AKRX: 47.28 (-0.25), MYL: 55.85 (+1.34), NVS: 102.20 (-0.17)
Taro Announces Results of Its Annual General Meeting of Shareholders
Business Wire - Wed Dec 24, 12:30PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"
announced that the Company held its annual general meeting of shareholders on December 22, 2014, at the offices of Meitar Liquornik Geva Leshem Tal, located at 16 Abba Hillel Road, Gallery Floor, Ramat Gan (the "Annual General Meeting" . TARO: 161.14 (-1.44)
Stock Movers: Why 4 Big Drug Stocks Are Rising Today
at Investor's Business Daily - Tue Nov 18, 1:38PM CST
Drugmakers clustered near the top of IBD's Stocks On The Move list Tuesday afternoon. Actavis (ACT), an Ireland-based maker of generic and branded drugs, shot up more than 7% in huge volume in Tuesday afternoon trading on the stock market today. That...
AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), TARO: 161.14 (-1.44), GILD: 101.90 (+1.10)
Taro Pharmaceutical Industries' (TARO) CEO Kal Sundaram on Q2 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:07PM CST
TARO: 161.14 (-1.44)
Taro Pharma ups earnings 49% in FQ2
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 12:48PM CST
TARO: 161.14 (-1.44)
Taro Pharmaceutical EPS of $3.35
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:43AM CST
TARO: 161.14 (-1.44)
Taro Provides Results for September 30, 2014
Business Wire - Sun Nov 09, 10:36AM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"
today provided unaudited financial results for the three months and six months ended September 30, 2014. TARO: 161.14 (-1.44)
Taro reports November 9
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:42PM CST
TARO: 161.14 (-1.44)
Taro to Announce Second Quarter Results on November 9, 2014
Business Wire - Wed Nov 05, 2:26PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2014, on Sunday, November 9, 2014.
TARO: 161.14 (-1.44)
Use The Relative Strength Line To Qualify A Breakout
at Investor's Business Daily - Wed Oct 29, 5:40PM CDT
Stock charts are a collection of facts and tools: price, volume, moving averages. All of them help you understand how a stock and its investors are responding to market input and supply and demand. One very helpful but often lesser-used tool is the...
TARO: 161.14 (-1.44)
Glaucoma Market Analysis 2014-2015 - API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Oct 02, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qn2l4v/glaucoma_market) has announced the addition of the "Glaucoma- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Glaucoma- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Allergan, Inc. - Merck & Co., Inc. - Alcon, Inc. - Taro Pharmaceutical Industries Ltd. - Pharmacia & Upjohn, Inc. - Teva Pharmaceuticals USA, Inc. - Akorn, Inc. - Pfizer Inc. - Alcon Laboratories, Inc. - Bausch & Lomb Incorporated - JHP Pharmaceuticals, LLC - Mobius Therapeutics, LLC - American Regent, Inc. For more information visit http://www.researchandmarkets.com/research/qn...oma_market
AGN: 229.49 (+1.87), TARO: 161.14 (-1.44), AKRX: 47.28 (-0.25), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07)
Taro Provides Results for Quarter Ended June 2014
Business Wire - Thu Aug 07, 5:47PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"
today provided unaudited financial results for the three month period ended June 30, 2014. TARO: 161.14 (-1.44)
